eligibility_summary
Key eligibility: histologically/cytologically confirmed metastatic NSCLC, ≥1 measurable, non-irradiated lesion (RECIST v1.1), definitively treated, stable, asymptomatic brain mets allowed if ≥2 weeks and on ≤10 mg prednisone, prior malignancy allowed, ECOG 0–1. Exclude: Phase 2 with known driver mutations, palliative RT <14 days, leptomeningeal disease or untreated cord compression, ILD/pneumonitis, significant allergy/hypersensitivity to amivantamab/docetaxel/polysorbate/paclitaxel.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06532032 tests a combination of: 1) Amivantamab (JNJ-61186372), an IV bispecific IgG1 monoclonal antibody targeting EGFR and MET. Mechanisms: binds EGFR/MET extracellular domains to block ligand binding and downstream signaling, promotes receptor internalization/degradation, and induces immune effector killing (ADCC/trogocytosis) via Fcγ receptor–bearing cells (NK cells/macrophages). 2) Docetaxel (Taxotere), an IV taxane chemotherapeutic that stabilizes microtubules, preventing depolymerization and causing mitotic arrest/apoptosis. Targets/pathways: EGFR/MET receptor tyrosine kinase pathways (MAPK/ERK, PI3K/AKT) on NSCLC tumor cells, immune cell–mediated cytotoxicity, microtubules in rapidly dividing tumor cells. Phase 1 determines RP2CD, Phase 2 tests efficacy in metastatic NSCLC without oncogenic drivers after platinum and ICI.